Novo Nordisk's Obesity Therapy Shows Superior Lean Mass Preservation Over Eli Lilly Rival

A new real-world data study suggests that while Eli Lilly's tirzepatide may drive greater overall weight loss, Novo Nordisk's semaglutide is more effective at maintaining lean body mass. This finding introduces a critical clinical distinction in the competitive GLP-1 weight-loss market.

• Tirzepatide leads to greater overall weight loss
• Semaglutide demonstrates better preservation of lean body mass
• Study utilizes real-world data rather than controlled clinical trials
• Lean mass preservation is critical for long-term metabolic health
• Findings may shift competitive dynamics in the GLP-1 sector